AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23444963
Drug: High kimchi
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High kimchi intake (210 g/day)
Trial: 23444963
Drug: Low kimchi
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low kimchi intake (15 g/day)
Trial: 19173710
Drug: Alanine-glutamine infusion
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alanine-glutamine infusion at a rate of 0.025 g/(kg body weight x hour) for 10 hours
Trial: 17365735
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 21 mg/day
Trial: 17365735
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 42 mg/day
Trial: 9006598
Drug: Nurse-initiated daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-initiated daily phone calls program
Trial: 8252685
Drug: Contrast agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast agents (general)
Trial: 3520469
Drug: Amoxicillin-clavulanate potassium
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate potassium (Augmentin)
Trial: 8053613
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (800 mg/d)
Trial: 27936344
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of HZ/su vaccine
Trial: 22012543
Drug: Magnesium Group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium Group (10% magnesium sulphate 2 mL)
Trial: 22012543
Drug: Saline Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Group (normal saline 2 mL)
Trial: 20889389
Drug: Study Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Care (SC): reassurance and avoidance of passive treatments, acetaminophen, 4 weeks of lumbar chiropractic spinal manipulative therapy (CSMT), and return to work within 8 weeks
Trial: 9650682
Drug: ACTH therapy
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH therapy (0.025 mg/kg/day, administered intramuscularly for 6 weeks, total dosage = 0.625 mg/kg)
Trial: 31015261
Drug: IL‐1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1 receptor antagonist (study B)
Trial: 21652615
Drug: i-gel™ with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel™ with Magill PVC tube
Trial: 17547798
Drug: Dixson 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dixson 0.75 kcal/ml (TPF-DM)
Trial: 17547798
Drug: Nutrition MF
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition MF 0.75 kcal/ml (standard formula)
Trial: 15337732
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d for 1 month followed by 80 mg/d thereafter
Trial: 21477202
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d
Trial: 25809332
Drug: Pectin 24
RxNorm normalized name: opium/kaolin/pectin 24 mg ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin 24 g powder/d (n=46)
Trial: 22303576
Drug: Dietetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietetic treatment for childhood obesity (8 sessions of an 8-hour family-centred group treatment programme based on behavioural change techniques)
Trial: 9327371
Drug: Standard plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard plus supplemental vitamin A (2.6 mumol/l [2500 IU] orally each day)
Trial: 27282488
Drug: Dithiothreitol (DTT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithiothreitol (DTT) treatment
Trial: 27282488
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution treatment
Trial: 22717217
Drug: Orlistat 60
RxNorm normalized name: orlistat 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 60 mg (three capsules daily with meals)
Trial: 20524987
Drug: TZP-101 80
RxNorm normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TZP-101 80 μg kg(‐1)
Trial: 18669453
Drug: Chemotherapy (fluorouracil/leucovorin)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (fluorouracil/leucovorin) with radiotherapy (50 Gy) and adjuvant for 16 weeks after surgery (CRT group, n = 98)
Trial: 12892687
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol 1 mg/day
Trial: 6518461
Drug: Bolar quinidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolar quinidine gluconate tablets (Bolar Pharmaceutical Company)
Trial: 29526860
Drug: expanded Constraint‐Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: expanded Constraint‐Induced Movement Therapy (eCIMT)
Trial: 23359966
Drug: External application
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External application of Compound Tripterygium wilfordii (CTW)
Trial: 12549945
Drug: On-site antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site antifungal susceptibility testing (AST)
Trial: 25376617
Drug: IBI‐20089 (6.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI‐20089 (6.9 mg or 13.8 mg TA) followed by ranibizumab (0.5 mg)
Trial: 25376617
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IBI‐20089 and ranibizumab)
Trial: 15095932
Drug: Nonenteric-coated aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonenteric-coated aspirin
Trial: 15095932
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa receptor inhibitors, unfractionated heparin (UFH), and clopidogrel (Plavix)
Trial: 15095932
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa receptor inhibitors (tirofiban, eptifibatide, abciximab)
Trial: 15095932
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive or early conservative therapy
Trial: 9768766
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 microg/kg (Group G)
Trial: 30661477
Drug: Roux-en-Y Gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux-en-Y Gastric Bypass (RYGB) combined with medical therapy
Trial: 21868796
Drug: Ice therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice therapy, NSAIDs, stretching and strengthening program
Trial: 21868796
Drug: Ice therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice therapy, NSAIDs, stretching and strengthening program, reinforced by acupuncture treatment
Trial: 18715283
Drug: NTX 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTX 0.125 mg
Trial: 18715283
Drug: NTX 0.250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTX 0.250 mg
Trial: 17917992
Drug: 8 hours
RxNorm normalized name: Thermacare Muscle/Joint 8 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 hours of training emphasizing interviewing behaviours in the diagnosis and treatment of depression and GAD
Trial: 9552221
Drug: i.v. methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. methylprednisolone (40 mg/day) and oral placebo (t.i.d.)
Trial: 9552221
Drug: Both i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both i.v. methylprednisolone and oral amoxicillin-clavulanic acid as above
Trial: 29633349
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (n = 188)
Trial: 28443383
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei strain Shirota (LcS) - 100 ml of LcS-fermented milk daily for 8 weeks prior to and 3 weeks after the exam
Trial: 28443383
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - non-fermented placebo milk daily for 8 weeks prior to and 3 weeks after the exam
Trial: 26311751
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment response
Trial: 24045248
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (craniocaudal scan direction with 120 mL contrast)
Trial: 19951554
Drug: L-arginine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine 400 mg group
Trial: 2644748
Drug: Atracurium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.1 mg.kg‐1) - up to 8 incremental doses
Trial: 729619
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Trial: 729619
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Trial: 25892145
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg/day)
Trial: 31501887
Drug: Methotrexate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (40 mg/m2/week)
Trial: 21275922
Drug: Non-OC phase
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-OC phase (hormone-free phase)
Trial: 19111408
Drug: ESR2 G‐G‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESR2 G‐G‐G haplotype (major allele for all polymorphisms)
Trial: 11455373
Drug: Postoperative ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative ibuprofen therapy (400 mg taken orally 1 hour before separator placement and a lactose capsule taken orally 6 hours after the initial dose)
Trial: 11455373
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preemptive and postoperative ibuprofen therapy (lactose capsule taken orally 1 hour before separator placement and 400 mg ibuprofen taken 6 hours after the initial placebo)
Trial: 11455373
Drug: Lactose capsule
RxNorm normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose capsule (control group)
Trial: 3053941
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (2 tabs daily for 6 weeks)
Trial: 18236783
Drug: Buccoadhesive film
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccoadhesive film containing 30 mg of ketorolac tromethamine (KT)
Trial: 9695137
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) 1 microgram/kg
Trial: 16287344
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g Cr + 20 g dextrose (Cr)
Trial: 30579992
Drug: Laser ablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser ablation and three times aminolaevulinic acid-based photodynamic therapy (ALA-PDT)
Trial: 22759488
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional anaesthesia
Trial: 19958629
Drug: rAd‐p53 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAd‐p53 injection combined with cisplatin
Trial: 26806546
Drug: ViveSoy® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ViveSoy® (500 mL per day, 15 g of protein, 50 mg of isoflavones)
Trial: 26516121
Drug: LY2495655 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2495655 (LY) 315 mg
Trial: 16413878
Drug: Iron (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (12.5 mg) and folic acid (50 microg)
Trial: 12794395
Drug: 5.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg rPAF‐AH
Trial: 12794395
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg rPAF‐AH
Trial: 1850208
Drug: Once-weekly psychotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly psychotherapy, family therapy, or group therapy led by paraprofessionals
Trial: 7140566
Drug: Cimetidine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1,000 mg/d)
Trial: 7140566
Drug: Antacids (magnesium-aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (magnesium-aluminium hydroxide, neutralization capacity 564 mmol/d)
Trial: 31957666
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (300,000 IU intramuscular injection)
Trial: 28964736
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg Q2W
Trial: 28964736
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg Q2W
Trial: 31708410
Drug: Alirocumab dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab dose increase to 150 mg Q2W
Trial: 31708410
Drug: Background statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background statin therapy
Trial: 28844193
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with warfarin, P2Y12 inhibitor, and aspirin
Trial: 28844193
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with dabigatran (both doses combined)
Trial: 26004431
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (dosage not specified)
Trial: 19104789
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day for 14 days)
Trial: 17076982
Drug: IM haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM haloperidol 6.5 mg
Trial: 10902797
Drug: Leptin levels
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin levels in peritoneal fluid (PF) (35.9 +/- 17.4 ng/mL)
Trial: 10902797
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group serum leptin levels (15.6 +/- 8.4 ng/mL)
Trial: 10902797
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group PF leptin levels (17.5 +/- 7.2 ng/mL)
Trial: 9017127
Drug: Small‐Carrion implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small‐Carrion implants
Trial: 29588232
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg slow-release propranolol
Trial: 23785525
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with annual mass treatment for three years (3×)
Trial: 23785525
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with stopping rule (SR)
Trial: 23785525
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment with annual mass treatment for three years (3×)
Trial: 23785525
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment with stopping rule (SR)
Trial: 23785525
Drug: One round
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One round of mass drug administration (MDA)
Trial: 12918544
Drug: Novel antiplatelet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel antiplatelet and anticoagulant strategies
Trial: 12918544
Drug: Novel agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel agents targeting haemostatic pathways
Trial: 12918544
Drug: New compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New compounds
Trial: 8796665
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses (0.075, 0.100, 0.150, 0.200 mmol/kg)
Trial: 28114979
Drug: Prolonged antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antibiotic therapy (15 days)
Trial: 26649908
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 0 mg (Control)
Trial: 26649908
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 50 mg
Trial: 26649908
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 100 mg
Trial: 19066345
Drug: Bicarbonate/lactate-based peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate/lactate-based peritoneal dialysis solution (P)
Trial: 2397543
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) treatment with herbs: Bupleurum chinense, Scutellaria baicalensis, Astragalus membranaceus, Codonopsis pilosula, Ligustrum lucidum, Lophatherum gracile, and thread of ivory, for 1-3 courses of treatment lasting one month each.
Trial: 28647684
Drug: Anti-H. pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H. pylori treatment at baseline
Trial: 24600204
Drug: Olmesartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (20 mg once daily for 16 weeks)
Trial: 24600204
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg once daily for 16 weeks)
Trial: 24600204
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg once daily for 16 weeks)
Trial: 22257505
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training using Threshold IMT device (G-1; n = 16)
Trial: 22257505
Drug: Biofeedback (G-2;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback (G-2; n = 15)
Trial: 11145492
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg daily
Trial: 19963436
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 100 mg daily
Trial: 18295343
Drug: Quetiapine switch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine switch (mean dose=290.0 mg/day, S.D.=55.2)
Trial: 18295343
Drug: Risperidone continuation
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone continuation (mean dose=4.1 mg/day, S.D.=1.2)
Trial: 11485375
Drug: L-NMMA with
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA with BQ-123
Trial: 28666463
Drug: Adjunctive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive treatment by homeopaths
Trial: 21862001
Drug: Mock TEAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock TEAS treatment (group I, n = 99)
Trial: 21862001
Drug: Single TEAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single TEAS treatment (group II, n = 110)
Trial: 17805062
Drug: Sequential Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential Docetaxel (75 mg/m2)
Trial: 17805062
Drug: Sequential Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential Docetaxel
Trial: 15070418
Drug: Methylphenidate 1
RxNorm normalized name: methylphenidate 17.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/day (with approximately 15 mg zinc element)
Trial: 15070418
Drug: Methylphenidate 1
RxNorm normalized name: methylphenidate 17.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg)
Trial: 12227888
Drug: Triptorelin (Decapeptyl)
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin (Decapeptyl) and goserelin (Zoladex) - GnRH agonists, 4-month treatment course
Trial: 2513206
Drug: Nicardipine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 80 mg/day
Trial: 2513206
Drug: Nifedipine 40
RxNorm normalized name: nifedipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 40 to 80 mg/day